Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Israel’s 'Stonehenge’ not alone with near 30 similar sites, satellite imagery reveals - 2Jillian Michaels put me at the center of a body positivity debate. She's not entirely wrong about obesity.
- 3Unwinding History's Secrets: Looking for the Response to Antiquated Human advancements
- 4Improving as a Pioneer: Examples from My Vocation
- 5Baidu robotaxi outage in Wuhan caused by 'system failure', police say
- 7 Well known Vacation spots In The US
- Manual for 6 famous sorts of cheddar
- Satellite space quiz: What's orbiting Earth?
- Most loved Road Food: Which One Prevails upon You?
- A Time of Careful Eating: Individual Tests in Nourishment
- Find Your Ideal Tea: Six Particular Assortments
- The most effective method to Plan an Incineration Administration: A Bit by bit Guide.
- Europe’s EV Boom Was Real in 2025. The Real Fight Starts In 2026
- Proficient Cultivating Devices for a Lovely and Useful Nursery in 2024
